ABOUT US
SCIENCE
FACILITY
INVESTORS
Media
Notice
Public Disclosures
Stock Information
Financials
ESG
ESG Management
Archive
CONTACT
ABOUT US
SCIENCE
FACILITY
INVESTORS
Media
Notice
Public Disclosures
Stock Information
Financials
ESG
ESG Management
Archive
CONTACT
INVESTORS
[머니투데이] 큐로셀, 국산 최초 CAR-T 승인 초읽기…상업화 넘어 적응증 확장도 순항
2025/08/11
큐로셀, 국산 최초 CAR-T 승인 초읽기…상업화 넘어 적응증 확장도 순항 – 머니투데이
Prev
큐로셀, 성인 ALL 대상 ‘안발셀’ IND 변경 신청… 임상 2상 개시 목적
Next
[한국경제] 큐로셀 “루푸스병 신약에 도전장”…토종 맞춤형 세포치료제 임상에 뛰어들다
ABOUT US
SCIENCE
FACILITY
INVESTORS
Media
Notice
Public Disclosures
Stock Information
Financials
ESG
ESG Management
Archive
CONTACT
ABOUT US
SCIENCE
FACILITY
INVESTORS
Media
Notice
Public Disclosures
Stock Information
Financials
ESG
ESG Management
Archive
CONTACT
Copyright 2023. Curocell Inc. All Rights Reserved.